EFSA review of risk to bees from neonicotinoid technology is fundamentally flawed

  EFSA review of risk to bees from neonicotinoid technology is fundamentally

PR Newswire

BASEL, Switzerland, Feb. 15, 2013

BASEL, Switzerland, Feb. 15, 2013 /PRNewswire/ --Syngenta today requested
that the European Commission retract its proposal to restrict the use of
neonicotinoid technology after revealing that the European Food Safety
Authority's (EFSA) report on the risks to bees from their use was
fundamentally flawed.

Syngenta submitted a response to the EFSA report in January. This showed that
EFSA failed to consider key information proving the safety of thiamethoxam
seed treatment for use on crops such as oilseed rape and sunflower.

Further review has now shown that EFSA based its assessment on unrealistic and
excessive seed planting rates between two and four times higher than would be
used under modern agricultural practice.

Had EFSA used normal sowing rates they would have concluded that the risk to
bees is extremely low and that in reality neonicotinoid technology does not
damage their health.

Syngenta's Chief Operating Officer, John Atkin, said: "The European Commission
has been using this flawed EFSA report to justify proposed restrictions on
this technology. These latest findings undermine the basis for such action,
which would bring considerable economic harm to growers and absolutely no
benefit to bees. The European Commission must halt the current process and
undertake a comprehensive review to identify the true risks to bee health."

Syngenta has written to all EU Member States and the European Commission to
inform them of these findings.

For more information on the bee health challenge go to www.plightofthebees.com

Syngenta is one of the world's leading companies with more than 27,000
employees in over 90countries dedicated to our purpose: Bringing plant
potential to life. Through world-class science, global reach and commitment to
our customers we help to increase crop productivity, protect the environment
and improve health and quality of life. For more information about us please
go to www.syngenta.com

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by
terminology such as 'expect', 'would', 'will', 'potential', 'plans',
'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such
statements may be subject to risks and uncertainties that could cause the
actual results to differ materially from these statements. We refer you to
Syngenta's publicly available filings with the U.S. Securities and Exchange
Commission for information about these and other risks and uncertainties.
Syngenta assumes no obligation to update forward-looking statements to reflect
actual results, changed assumptions or other factors. This document does not
constitute, or form part of, any offer or invitation to sell or issue, or any
solicitation of any offer, to purchase or subscribe for any ordinary shares in
Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on
in connection with, any contract therefor.

Syngenta International AG Media contacts:          Analyst/Investor contacts:
Media Office              Paul Barrett             Jennifer Gough
CH-4002 Basel             Switzerland +41 61 323   Switzerland +41 61 323 5059
Switzerland                                        USA +1 202 737 6521
Tel: +41 61 323 2323
Fax: +41 61 323 2424      Daniel Braxton           Lars Oestergaard
                          Switzerland +41 61 323   Switzerland +41 61 323 6793
www.syngenta.com                                   USA +1 202 737 6520

SOURCE Syngenta

Website: http://www.syngenta.com
Press spacebar to pause and continue. Press esc to stop.